ID
36076
Description
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab; ODM derived from: https://clinicaltrials.gov/show/NCT02422199
Lien
https://clinicaltrials.gov/show/NCT02422199
Mots-clés
Versions (1)
- 14/04/2019 14/04/2019 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
14 avril 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility HER2 Positive Metastatic Breast Cancer NCT02422199
Eligibility HER2 Positive Metastatic Breast Cancer NCT02422199
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
lapatinib | neratinib | pyrotinib | HER2 Targeted Tyrosine kinase inhibitor
Type de données
boolean
Alias
- UMLS CUI [1]
- C1506770
- UMLS CUI [2]
- C2713008
- UMLS CUI [3]
- C3828434
- UMLS CUI [4,1]
- C0069515
- UMLS CUI [4,2]
- C1521840
- UMLS CUI [4,3]
- C1268567
Description
capecitabine
Type de données
boolean
Alias
- UMLS CUI [1]
- C0671970
Similar models
Eligibility HER2 Positive Metastatic Breast Cancer NCT02422199
- StudyEvent: Eligibility
C1265611 (UMLS CUI [1,2])
C2348909 (UMLS CUI [1,2])
C1514463 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
C1514873 (UMLS CUI [1,2])
C0032181 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
C1278039 (UMLS CUI [4])
C0201899 (UMLS CUI [2])
C0005845 (UMLS CUI [3])
C0373595 (UMLS CUI [4])
C0428772 (UMLS CUI [5])
C1882513 (UMLS CUI [6])
C0079399 (UMLS CUI [7])
C2713008 (UMLS CUI [2])
C3828434 (UMLS CUI [3])
C0069515 (UMLS CUI [4,1])
C1521840 (UMLS CUI [4,2])
C1268567 (UMLS CUI [4,3])